Dr. Kang Jianlei, Vice President of Leadingpharm, Invited to Attend the 2025 Industry Technology Innovation Seminar of Strategic Alliance for Veterinary Pharmaceutical Industry Technology Innovation (SAVP) and Deliver a Thematic Report

From October 24 to 26, the 2025 Industry Technology Innovation Seminar of Strategic Alliance for Veterinary Pharmaceutical Industry Technology Innovation (SAVP) cum Industry Quality and Global Competition & Cooperation Innovation Forum was grandly held. Focusing on the optimization of veterinary drug industry policies, international registration, and R&D innovation, the conference specially invited Dr. Kang Jianlei, Vice President and Chief Technology Officer of Leadingpharm, to attend and deliver a thematic report titled "Evolution of Human Drug Regulatory Policies and Insights for Veterinary Drug Policies" to empower the development of the industry.

▲ Dr. Kang Jianlei

At present, the global pharmaceutical industry is accelerating its innovation evolution, and the coordination of international drug supervision is continuously deepened. China's veterinary drug industry has also entered a critical stage of improving quality and efficiency, strengthening independent innovation, and accelerating the internationalization process. Dr. Kang Jianlei systematically introduced the evolution of regulations and technical requirements in the human drug field over the past 30 years, providing references for veterinary drug industry policies and project-based R&D:

1. The continuous optimization and upgrading of registration regulations and classification, as well as the opportunities and challenges faced by the industry;
2. The core orientation of the industry remains to encourage innovation. Systems such as the Marketing Authorization Holder (MAH) system, implicit clinical trial approval, and priority review have established a review and approval system centered on clinical needs, prioritizing quality, and encouraging innovation;
3. The selection of generic drug R&D projects should be optimized based on industrial policies and enterprise characteristics, and sustained efforts are required in this regard.

▲ Dr. Kang Jianlei

This trip to Nanjing not only represents Dr. Kang Jianlei's in-depth exploration of the coordinated development of "human drugs - veterinary drugs" but also reflects Leadingpharm's core philosophy of fulfilling its industrial responsibilities. Currently, China's veterinary drug industry is in a critical stage of transformation and upgrading. Leadingpharm will continue to rely on its mature R&D experience and quality control system in the human drug field to inject more innovative impetus into the high-quality development of the veterinary drug industry!
 

▲ Group Photo of Participants

-END-